Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?

  • Ahmed, Rifat Zubair (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation) ;
  • Rashid, Munazza (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation) ;
  • Ahmed, Nuzhat (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation) ;
  • Nadeem, Muhammad (Centre of Excellence in Molecular Medicine, National Institute of Blood Disease and Bone Marrow Transplantation) ;
  • Shamsi, Tahir Sultan (Department of Postgraduate Studies and Research, National Institute of Blood Disease and Bone Marrow Transplantation)
  • Published : 2016.04.11
Download PDF
⟨ Previous Next ⟩

Abstract

The classic BCR-ABL1-negative myeloproliferative neoplasm is an operational sub-category of MPNs that includes polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). The JAK2V617F mutation is found in ~ 95% of PV and 50-60% of ET or PMF. In most of the remaining JAK2V617F-negative PV cases, JAK2 exon 12 mutations are present. Amongst the JAK2V617F-negative ET or PMF 5-10% of patients carry mutations in the MPL gene. Prior to 2013, there was no specific molecular marker described in the remaining 30-40% ET and PMF. In December 2013, two research groups independently reported mutations in the gene CALR found specifically in ET (67-71%) and PMF (56-88%) but not in PV. Initially CALR mutations were reported mutually exclusive with JAK2 or MPL. However, co-occurrence of CALR mutations with JAK2V617F has been reported recently in a few MPN cases. Many studies have reported important diagnostic and prognostic significance of CALR mutations in ET and PMF patients and CALR mutation screening has been proposed to be incorporated into WHO diagnostic criteria for MPN. It is suggestive in diagnostic workup of MPN that CALR mutations should not be studied in MPN patients who carry JAK2 or MPL mutations. However JAK2V617F and CALR positive patients might have a different phenotype and clinical course, distinct from the JAK2-positive or CALR-positive subgroups and identification of the true frequency of these patients may be an important factor for defining the prognosis, risk factors and outcomes for MPN patients.

Keywords

References

  1. Al Assaf C, Van Obbergh F, Billiet J, et al (2015). Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations. Haematologica, 100, 893-7. https://doi.org/10.3324/haematol.2014.118299
  2. Fu R, Xuan M, Zhou Y, et al (2014). Analysis of CALReticulin mutations in Chinese patients with essential thrombocythemia: clinical implications in diagnosis, prognosis and treatment. Leukemia, 28, 1912-4. https://doi.org/10.1038/leu.2014.138
  3. Guglielmelli P, Nangalia J, Green AR, et al (2014). CALR mutations in myeloproliferative neoplasms: Hidden behind the reticulum. Am J Hematol, 89, 453-6. https://doi.org/10.1002/ajh.23678
  4. Ha JS, Kim YK (2015). CALReticulin exon 9 mutations in myeloproliferative neoplasms. Ann Lab Med, 35, 22-7. https://doi.org/10.3343/alm.2015.35.1.22
  5. Klampfl T, Gisslinger H, Harutyunyan AS, et al (2013). Somatic mutations of CALReticulin in myeloproliferative neoplasms. New Engl J Med, 369, 2379-90. https://doi.org/10.1056/NEJMoa1311347
  6. Kralovics R (2008). Genetic complexity of myeloproliferative neoplasms. Leukemia, 22, 1841-8. https://doi.org/10.1038/leu.2008.233
  7. Lim KH, Chang YC, Gon-Shen CC, et al (2015). Frequent CALR exon 9 alterations in JAK2 V617F-mutated essential thrombocythemia detected by high-resolution melting analysis. Blood Cancer J, 5, 295. https://doi.org/10.1038/bcj.2015.21
  8. Lin Y, Liu E, Sun Q, et al (2015). The prevalence of JAK2, MPL, and CALR mutations in Chinese patients with BCR-ABL1-negative myeloproliferative neoplasms. Am J Clin Path, 144, 165-71. https://doi.org/10.1309/AJCPALP51XDIXDDV
  9. Lundberg P, Karow A, Nienhold R, et al (2014). Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood, 123, 2220-8. https://doi.org/10.1182/blood-2013-11-537167
  10. McGaffin G, Harper K, Stirling D, McLintock L (2014). JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol, 167, 276-8. https://doi.org/10.1111/bjh.12969
  11. Nangalia J, Massie CE, Baxter EJ, et al (2013). Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New Engl J Med, 369, 2391-405. https://doi.org/10.1056/NEJMoa1312542
  12. Rashid M, Ahmed RZ, Ahmed S, et al (2015). Coexisting JAK2 V617F and CALR exon 9 mutation in essential thrombocythemia. 2015 ASH Meeting on Hematologic Malignancies, 56.
  13. Rotunno G, Mannarelli C, Guglielmelli P, et al (2014). Impact of CALReticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 123, 1552-5. https://doi.org/10.1182/blood-2013-11-538983
  14. Shirane S, Araki M, Morishita S, et al (2015). JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica, 100, e46-8. https://doi.org/10.3324/haematol.2014.115113
  15. Tafferi A, Pardanani A (2014).CALR mutations and a new diagnostic algorithm for MPN. Nat Rev ClinOncol, 11, 125-6.
  16. Tefferi A (2010) Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia, 24, 1128-38. https://doi.org/10.1038/leu.2010.69
  17. Tefferi A, Lasho TL, Finke CM, et al (2014a).CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 28, 1472-7. https://doi.org/10.1038/leu.2014.3
  18. Tefferi A, Lasho TL, Tischer A, et al (2014b). The prognostic advantage of CALReticulin mutations in myelofibrosis might be confined to type 1 or type 1-like CALR variants. Blood, 124, 2465-6. https://doi.org/10.1182/blood-2014-07-588426
  19. Tefferi A, Thiele J, Vannuccji AM, et al (2014c). An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms. Leukemia, 28, 1407-13. https://doi.org/10.1038/leu.2014.35
  20. Vainchenker W, Delhommeau F, Constantinescu SN, et al (2011). New mutations and pathogenesis of myeloproliferative neoplasms. Blood, 118, 1723-35. https://doi.org/10.1182/blood-2011-02-292102
  21. Vardiman JW, Thiele J, Arber DA, et al (2009). The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood, 114, 937-51. https://doi.org/10.1182/blood-2009-03-209262
  22. Wu Z, Zhang X, Xu X, et al (2014). The mutation profile of JAK2 and CARL in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms. J Hematol Oncol, 7, 1-10. https://doi.org/10.1186/1756-8722-7-1
  23. Xu N, Ding L, Yin C, et al (2015). A report on the co-occurrence of JAK2V617F and CALR mutations in myeloproliferative neoplasm patients. Ann Hematol, 94, 865-7. https://doi.org/10.1007/s00277-014-2248-0
  24. Zamora L, Xicoy B, Cabezon M, et al (2015). Co-existence of JAK2 V617F and CALR mutations in primary myelofibrosis. Leuk Lymphoma, 11, 1-2.

Cited by

  1. Parallel algorithm for myeloproliferative neoplasms testing: the frequency of double mutations is found in the JAK2/MPL genes more often than the JAK2/CALR genes, but is there a clinical benefit? vol.0, pp.0, 2019, https://doi.org/10.1515/cclm-2018-0232